This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Auxilium CEO Goes Against Type, Buying Instead of Selling

CHESTERBROOK, Penn. ( TheStreet) -- Adrian Adams was named chief executive officer of Auxilium Pharmaceuticals (AUXL) in December 2011 with the reputation as a great salesman. His prior CEO posts at Inspire Pharmaceuticals, Kos Pharmaceuticals and Sepracor had all ended with the companies being bought out for handsome premiums. Naturally, investors speculated Adams would do the same with Auxilium.

Except Adams hasn't sold Auxilium. Instead, the salesman has turned into a buyer. On Monday, Auxilium acquired privately held Actient Holdings, a marketer of urology products, for $585 million in cash plus Auxilium stock contingencies and warrants.

Auxilium shares are down 7% to $14.89 in early Monday trading.

Adams, in a statement, says the Actient deal will expand Auxilium's drug portfolio, accelerates the company's growth and will be immediately accretive to the company's adjusted earnings.

But the timing of the deal also comes as Auxilium's base business is weakening. The company reported net total revenue of $66.2 million in the first quarter, a 10% drop from one year ago. Analysts were expected revenue of $81.23 million the quarter, so reported sales missed expectations by a wide margin.

Both of Auxilium's core products were weak. Sales of Testim, a testosterone replacement therapy for men, fell 23% year over year; sales of Xiaflex, which treats Dupuytren's contracture, dropped 10%.

Auxilium lowered revenue guidance for both Testim and Xiaflex for the remainder of 2013.

With that context, Auxilium acquires Actient Holdings, which sells six products, including a long-acting implantable testosterone therapy and a vacuum pump that helps men achieve erections. Total revenue in 2012 was $125 million, so on the cash basis alone, Auxilium is paying just under five times sales to acquire Actient.

Adding in Actient revenue, Auxilium is now forecasting 2013 revenue in the range of $360 million to $415 million, up from previous guidance of $325 million to $355 million. Auxilium won't say how much the Actient acquisition will add to the bottom line, only that it will be "accretive" to the company's previous 2013 guidance of net income of $18 million to $23 million on a non-GAAP basis.

-- Reported by Adam Feuerstein in Boston.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AUXL $36.47 -0.16%
AAPL $93.74 0.00%
FB $117.58 0.00%
GOOG $693.01 0.00%
TSLA $240.76 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs